Prolactin-releasing peptide and corticotrophin-releasing hormone R-00402-2003.R1
Prolactin-releasing peptide (PrRP) was first identified to be the endogenous ligand for the human orphan receptor, GPR10/hGR3 (or UHR-1 in the rat), and was reported to display specific prolactin-releasing properties (15) . PrRP mRNA and immunoreactive cell bodies are located exclusively in three brain regions, the dorsomedial hypothalamus (DMH), and in the nucleus tractus solitarius (NTS) and the ventrolateral medulla of the brainstem (2, 7, 18, 26, 30, 33, 39, 60) . UHR-1 receptor (PrRP-R) mRNA is also found in the rat brain, and is expressed most highly in the reticular nucleus of the thalamus, the periventricular hypothalamic nucleus, paraventricular hypothalamic nucleus (PVN), DMH, NTS and the area postrema (7, 19, 22, 39) . PrRP-immunoreactive fibers are detected in several brain regions that express PrRP-R mRNA, including the PVN and the periventricular hypothalamic nucleus (18, 30, 60) .
We have proposed a role for PrRP in energy homeostasis, since mRNA for the peptide is reduced, typically for an anorectic peptide, in states of negative energy balance (fasting and lactation) and in the obese Zucker rat (5, 22) . Intracerebroventricular (icv) administration of PrRP reduces both fast-induced and spontaneous feeding, and body-weight gain in rats (5, 22, 23, 47) . Furthermore, PrRP does not appear to affect feeding via non-specific or non-homeostatic actions, as it does not support conditioned taste aversion or disrupt the behavioral satiety sequence (23) . Pair-feeding experiments suggest that the reduction in body weight after icv injection of PrRP is not due entirely to its anorectic actions (22) , implying that PrRP may have additional effects, possibly on energy expenditure. In support of this idea, PrRP affects core body temperature, and hyperthermia is observed typically 2-8 h after icv injection (5, 22) . However, an increase in body temperature is only an indicator that PrRP is increasing energy expenditure, and more direct evidence based on oxygen consumption needs to be determined.
The mechanisms of PrRP's action on appetite and body temperature are unknown. It is unlikely that prolactin itself is a mediator as several groups have demonstrated that PrRP does not, or can only weakly, cause prolactin release both in vivo and in vitro (19, 32, 42-44, 48, 54) . One possible downstream mediator is corticotropin-releasing hormone (CRH). Like PrRP, central administration of CRH reduces food intake and body weight [see (13) ], and modifies energy expenditure in rodents [see (3, 12, 41) ]. PrRP-immunoreactive fibres appear to make synaptic contact with CRH-containing cell bodies in the rat PVN, providing morphological evidence for a relationship between the two neuropeptides (31). Furthermore, icv injection of PrRP increases neuronal activation (measured by induction of c-Fos expression) in the PVN of the rat (23) , including in approximately 80% of CRHcontaining neurons (31), and in vitro PrRP increases hypothalamic CRH release (46) .
In addition, central administration of PrRP in rats stimulates plasma levels of ACTH, an effect that is dependent on CRH receptor activation (31, 46), and corticosterone (42). In view of the above, we hypothesized that the actions of PrRP on energy balance are mediated via CRH receptors.
Therefore, the main aim of this study was to test the hypothesis that central CRH receptors mediate the effects of PrRP on food intake and core body temperature. Another anorectic pathway, the melanocortin system, was considered since it partially mediates the effects of modulators such as leptin (11, 16, 45, 49) , and because the acute actions of leptin and PrRP are very similar (5) . Additionally, the effect of PrRP on energy metabolism was tested more directly by measuring oxygen consumption using closed-circuit calorimetry.
METHODS

Materials.
Rat Measurement of oxygen consumption. Oxygen consumption (VO 2 ) was determined in closed-circuit respirometers maintained at the thermoneutral temperature for rats (29 ºC). The system allows eight rats to be tested individually at one time (52) . All animals were accustomed to the respirometers and procedures on two occasions the week before the experiments. A week after lateral ventricle cannulation animals were housed individually, without food, in the respirometers and The mean change in VO 2 from baseline over the 3 h period was calculated for statistical analysis.
Statistical comparisons were performed using an unpaired Student's t-test for two groups (Experiment 3, and Experiment 4, Fig. 5B ), and all other experiments were analyzed using a one-way ANOVA, followed by a Tukey-Kramer comparisons post hoc test. Statistical significance assumed a two -tailed probability with a P < 0.05.
RESULTS
Experiment 1: Effect of a CRH receptor antagonist on PrRP actions on food intake and core body temperature. Central injection of the CRH receptor antagonist, astressin (20 µg), alone had no effect on food intake at the 0-1 h and 1-2 h time points compared with vehicle-treated animals ( Fig. 1) . Administration of PrRP (4 nmol) suppressed food intake at 1 h (67%) after injection when compared with vehicle-injected animals, but there was no difference in the second hour. Astressin reversed the effects of PrRP on food intake at 1 h, and values for the PrRP plus astressin co-injected group was not significantly different from control animals.
Remote radiotelemetry revealed that fasted animals, injected icv with vehicle, reliably displayed an initial hyperthermia (over approximately 2 h) probably due to increased feeding activity when food was returned. Astressin alone had no significant effect on core body temperature during the experimental period, although the graphs suggest that there was a steady, but non-significant, rise (over 2-8 h) in body temperature in this group of animals (AUC for 2-8 h: vehicle, 2.82 ± 0.36 ºC h versus astressin, 4.06 ± 0.83 ºC h, P > 0.05, Fig. 2A ). Injection of PrRP caused an initial hypothermic response followed by a significant increase in core body temperature over 2-8 h compared with vehicle injection (AUC for 2-8 h: vehicle, 2.82 ± 0.36 ºC h versus PrRP, 5.58 ± 0.88 ºC h, P < 0.05, Fig. 2B ). Co-injection of astressin prevented the initial hypothermic response induced by PrRP (Fig. 2C) . However, core body temperature observed during the 2-8 h after PrRP plus astressin was also significantly greater compared with vehicle injection (AUC for 2-8 h: vehicle, 2.82 ± 0.36 ºC h versus PrRP + astressin, 5.84 ± 0.99 ºC h, P < 0.05, Fig. 2C ). There was no significant difference between the AUC for the PrRP alone and PrRP plus astressin groups (P > 0.05).
Experiment 2: Effect of a melanocortin receptor-3/4 antagonist on PrRP actions on food intake and core body temperature. Icv injection of SHU9119 alone had no effect on 0-1 h or 1-2 h fast-induced feeding (Fig. 3 ). PrRP caused a significant reduction in 1 h (56%) food intake compared with vehicle-treated rats and as reported for Experiment 1, there was no effect on feeding during 1-2 h after injection (Fig. 3) . However, co-injection of SHU9119 had no effect on the decrease in food intake observed after injection of PrRP. Food intake in this group of animals was reduced by 51% at 1 h versus vehicle-treated groups, and was not significantly different when compared with PrRP injection alone (Fig. 3) . Food intake was also measured for up to 8 h after injections, and that confirmed that SHU9119 did not have any delayed effect on the PrRP response (data not shown).
SHU9119 alone also had no significant effect on the change in body temperature compared with vehicle-treated animals (AUC for 2-8 h: vehicle, 3.04 ± 0.27 ºC h versus SHU9119, 4.41 ± 0.49 ºC h, P > 0.05, Fig. 4A ). As expected PrRP administration caused a characteristic drop in core body temperature (Fig. 4B ). This This decline is normal, and probably reflects a decrease in the diet-induced thermogenesis resulting from the last few nocturnal meals consumed just before the start of the light phase (0800 h). This decline, however, was less in animals that received PrRP, and VO 2 was significantly greater than in vehicle-treated animals for the 3 h measurement period. 
DISCUSSION
We have shown previously that icv injection of PrRP reduces food intake and body weight, and modifies core body temperature in fasted and ad libitum fed rats (5,
22, 23). The acute effects of PrRP on food intake, which occur within 1 h of injection,
have been confirmed by Seal and co-workers (47) and here in the present study. The CRH receptor antagonist, astressin, but not the melanocortin-3/4 receptor antagonist, SHU9119, blocked the effect of PrRP on food intake. Agonists of melanocortin receptor-3/4 (e.g., α-melanocyte stimulating hormone, MTII) suppress food intake in rodents (6, 55) . The dose of the antagonist, SHU9119, used in the present experiment (0.1 nmol) is effective as it blocks the anorectic actions of an equimolar injection of the melanocortin receptor agonist, MTII (24) . Furthermore, it has its effect when it is co-administered at the same time with either MTII, leptin or d-fenfluramine (14, 24, 45) . Since higher doses of SHU9119 can initiate food intake at later time points (9, 40), we confirmed also that it did not reverse the effect of PrRP on cumulative food intake over an 8 h period.
The effect of PrRP on core body temperature is two-fold, as after an initial, brief hypothermic period a hyperthermic phase is evident. Data presented here and previously (4, 5, 22) demonstrate that the temperature profile observed after PrRP is the same regardless of when injections are performed (light phase versus dark phase), and whether the animals are eating or not. Since astressin reversed both the initial drop in body temperature and the reduction in food intake observed after PrRP injection, it is possible that the hypothermic response is responsible for the ensuing effects on feeding. However, we observe similar acute hypothermic phases after icv injection of several other neuropeptides, which are conversely orexigenic, that is they stimulate feeding [e.g., growth hormone releasing peptide-6 and ghrelin; (25)]. Thus, the acute hypothermia is neither sufficient to cause a reduction in feeding, nor is it a result of reduced feeding. The subsequent increase in core body temperature was not significantly inhibited by astressin, though these results are complicated by the fact that astressin itself has a thermogenic effect.
Increases in core body temperature may be indicative of heightened energy expenditure and we now provide more direct evidence for this, as PrRP increased oxygen consumption, at least acutely. These results therefore demonstrate that There are several CRH receptor subtypes described to date; CRH receptor type 1 and CRH receptor type 2, which can exist as several splice variants, see (37, 56) . The CRH receptor subtype involved in PrRP's anorectic effects cannot be ascertained from this study, as the antagonist, astressin, does not distinguish between the two (10, 36). Likewise, the actions of PrRP cannot be conclusively ascribed to CRH since there are several other endogenous ligands that act at CRH receptors. These include, urocortin (58) , and the recently identified urocortin II (17, 38) and urocortin III (17, 27) . Each of these neuropeptides affect feeding in rodents (17, 38, 51) and, thus, could potentially be involved in PrRP's anorectic actions. This stated, CRH's involvement is supported by the observation that 80% of CRHcontaining neurons in the PVN are activated by icv injection of PrRP (31), and in vitro PrRP causes hypothalamic CRH release (46) . However, actions of PrRP in the PVN may not be direct, since although PrRP-R mRNA is located in this area (19, 22, 39) and PrRP-immunoreactive fibers make synaptic contact with CRH cell bodies in the PVN (31), a recent study suggests that only a small percentage of PrRP-R expressing cells in the PVN contain CRH (28). Thus, the described effects of PrRP in the PVN may be indirect due to activation of neuronal pathways that connect with the PVN.
Both CRH and urocortin induce a range of behaviors, such as anxiety and hyperactivity, when administered centrally (21, 50) . Thus, the significance of CRH and the urocortins in the physiological regulation of food intake is still debatable. Our own data demonstrate that, in addition to the PVN, increases in c-Fos after icv PrRP injection are observed in the amygdala (23) , which is also a major site of CRH synthesis (53) . Although, we propose a role for CRH receptors in the actions of PrRP on feeding, the caveat noted above might indicate that PrRP can affect appetite, possibly by causing anxiety. However, we have demonstrated that PrRP, at doses that decrease feeding, enhances the behavioral satiety sequence, and does not cause conditioned taste aversion (23), or affect water intake (22, 43) . In addition,
Seal and colleagues have demonstrated that PrRP, at comparable doses, does not affect overt behaviors significantly (47) . We have demonstrated recently that repeated doses of PrRP lead to tolerance to the anorectic action (4). However, we do note that one study failed to reproduce the acute effects of PrRP on feeding at doses used in our own and the experiments of Seal and co-workers (59). These workers did report an effect with repeated central injections of PrRP at higher dose.
The acute effects of PrRP on feeding and body temperature are similar to those reported after central administration of leptin (5, 29) , and leptin actions on food intake are partially blocked by either CRH receptor antagonists (8, 57) or an anti-CRH antibody (34) . However, in contrast to PrRP, leptin also functions through melanocortin receptors (11, 16, 45, 49) . We have shown previously that leptin and
PrRP have an additive interaction when co-administered (5) and, thus, CRH receptors may be a point of convergence for these two catabolic factors. rats at 1000 h. Food intake was measured at 1 h and 2 h after injection. Data are mean ± SEM for n = 15-18 rats per group. * P < 0.05, ** P < 0.01 versus vehicle; ## P < 0.01, ### P < 0.001 versus SHU9119. 
